Most patients with decompensated cirrhosis who received inadequate prognostic information about their condition reported higher symptom burden and lower HRQOL.
In a series of studies at McMaster, Dr. Schertzer’s research group demonstrated that treatment with QBECO SSI resulted in a marked reduction in liver fat, inflammation, and fibrosis in fatty liver ...
While there is ongoing research to develop better tools like biochemical markers to differentiate fibrosis stage in MASH patients, the only standard currently used in MASH clinical studies involves ...